The industry’s latest
regulatory milestones.

Regulatory News Spotlight FDABiosimilar approval Xbrane Wins FDA Nod for Lucamzi Eye Biosimilar FDA approved the Swedish biotech’s ranibizumab biosimilar on 29 October 2026, exactly on its target decision date and a year after a manufacturing-related rejection — Xbrane’s first US approval, eighteen years after its founding, for a drug already sold across Europe since 2023 as Ximluci. Oct 29, 2026Read more Regulatory News Spotlight FDAFast Track Medicovestor Earns FDA Fast Track for Pancreatic ADC The private New York biotech’s MC001, a dimeric antibody-drug conjugate aimed at folate receptor alpha, picked up Fast Track designation on 20 October 2026 — the third FDA nod for the program in sixteen months, and the clearest signal yet that a company nobody outside oncology circles has heard of is close to dosing its first patient. Oct 29, 2026Read more Regulatory News Spotlight FDANDA approval Cosette Earns Its First FDA Drug Approval With EVOXAC Cosette Pharmaceuticals, built almost entirely by acquiring other companies’ already-approved brands, has won FDA approval for an EVOXAC oral solution it developed itself — a 505(b)(2) filing for Sjögren’s-disease dry mouth that becomes the private drugmaker’s first New Drug Application, with U.S. availability expected by the end of 2026. Oct 28, 2026Read more Regulatory News Spotlight CMSMedicare reimbursement Lucid Begins Medicare Payment for EsoGuard DNA Test Medicare began paying $1,938.01 per test for Lucid Diagnostics’ EsoGuard Esophageal DNA Test on 22 October 2026 — a reimbursement decision, not an FDA approval, announced alongside a $15 million financing the company has tied to its own convertible notes. Oct 27, 2026Read more Regulatory News Spotlight FDABreakthrough Therapy Sumitomo Earns FDA Breakthrough Tag for Enzomenib FDA granted enzomenib (DSP-5336) Breakthrough Therapy Designation on 26 October 2026 for relapsed/refractory KMT2A-rearranged acute leukemia — the drug’s fourth FDA designation since 2022, won while two rival menin inhibitors already carry FDA approval in overlapping indications. Oct 27, 2026Read more Regulatory News Spotlight FDA510(k) clearance Elucid Wins FDA Clearance for Its FFR-IQ Software FDA cleared Elucid’s FFR-IQ software on 29 September 2026, folding plaque composition into a coronary CT blood-flow estimate — the third FDA-cleared FFR-CT product in the US, built on a predicate from HeartFlow, the company that sued Elucid the day after the clearance became public. Oct 27, 2026Read more Regulatory News Spotlight NasdaqIPO City Therapeutics Closes $230M Nasdaq IPO The Cambridge, Massachusetts RNAi developer upsized and fully exercised its underwriters’ option on 19 October 2026, closing at $230.0 million gross to fund a Factor XI-silencing anticoagulant candidate born from Ohio State University chemistry research. Oct 26, 2026Read more Regulatory News Spotlight FDA510(k) clearance RIVANNA Wins FDA Clearance for BoneEnhance AI The Charlottesville, Virginia company's new machine-learning layer segments bone in 3D ultrasound volumes and labels it on-screen — built, the company says, on an independent test of 233 scans from 173 subjects that scored 95 to 100 percent accurate. Oct 26, 2026Read more Regulatory News Spotlight FDABreakthrough Device Teleflex’s Freesolve Scaffold Wins 2nd Breakthrough Tag FDA granted Freesolve RMS a Breakthrough Device Designation for coronary use on 22 October 2026 — the resorbable magnesium scaffold's second such designation since Teleflex acquired the technology from Biotronik, with a 1,859-patient US pivotal trial already enrolling toward a future approval filing. Oct 26, 2026Read more Regulatory News Spotlight FDAFast Track Nuravax Wins FDA Fast Track for Alzheimer’s Vaccine The Irvine, California biotech’s AV-1959R targets amyloid-beta before cognitive symptoms appear — a prevention category with no approved product and, so far, no market forecast — built on a vaccine platform licensed from a nonprofit research lab in 2021. Oct 25, 2026Read more Regulatory News Spotlight FDA510(k) clearance Penumbra’s Lightning CAVT Clears FDA for DVT The Alameda, California device maker wins the first FDA clearance for a mechanical thrombectomy device to treat deep vein thrombosis, nine months into a pending $14.5 billion acquisition by Boston Scientific. Oct 25, 2026Read more Regulatory News Spotlight FDA510(k) clearance Coreline Soft Wins 13th FDA Clearance for Aortic AI The Seoul, South Korea company’s AVIEW Aorta Metrics automatically measures the aorta from a chest CT a radiologist already ordered — the thirteenth U.S. clearance for a chest-CT AI line built to read one scan for lung nodules, COPD, coronary calcium and now the aorta. Oct 24, 2026Read more Regulatory News Spotlight FDACommercial launch Eko Health Launches CORE 300 Hybrid AI Stethoscope The Emeryville, California company began U.S. sales on 22 October 2026 of a stethoscope that switches between analog listening and FDA-cleared, AI-assisted digital modes in a single chestpiece — its thirteenth-year answer to a clinical exam that has not fundamentally changed since 1816. Oct 24, 2026Read more Regulatory News Spotlight FDAFast Track designation Samsung Bioepis Earns FDA Fast Track for First ADC The Incheon, South Korea biosimilar maker's first self-developed novel medicine, an antibody-drug conjugate aimed at patients whose urothelial cancer has already escaped the market-leading Nectin-4 therapy, won FDA Fast Track designation on 21 October 2026 — fourteen years into a company built almost entirely on copying other companies' biologics. Oct 24, 2026Read more Regulatory News Spotlight Series A$37M financing Altay Raises $37M for First Oral FSHD Drug Altay Therapeutics closed a $37 million Series A on 14 October 2026, co-led by Sound Bioventures and HealthCap, to move DX5057 — what the company calls the first oral small-molecule inhibitor of DUX4 — into a Phase 1 safety study, a year after Fulcrum Therapeutics' rival oral candidate failed its own Phase 3 trial in the same rare muscle disease. Oct 23, 2026Read more Regulatory News Spotlight FDA510(k) clearance NeuroXT Clears FDA for Alzheimer’s Risk AI Tool The FDA cleared NEXT-Cue on 20 October 2026 as a Class II device — a Seoul-built AI model that reads a brain MRI alongside cognitive-test and demographic data to estimate a patient’s five-year risk of progressing from mild cognitive impairment to Alzheimer’s dementia, the company’s first FDA clearance and its entry into the US market. Oct 23, 2026Read more Regulatory News Spotlight MHRAGB authorization Arrowhead Wins UK Nod for Rare-Disease Drug Redemplo The MHRA authorized plozasiran (Redemplo) on 19 October 2026 for adults with familial chylomicronaemia syndrome — Great Britain is the fifth market, after the US, EU, Australia and Canada, to clear the Pasadena company’s first commercial drug, and the first territory where it now goes head-to-head with Ionis and Sobi’s rival Tryngolza on home turf. Oct 23, 2026Read more Regulatory News Spotlight Series D$135M financing Nouscom Raises $135M for Cancer-Prevention Vaccine The Basel biotech's oversubscribed Series D funds a single global pivotal trial of NOUS-209, an off-the-shelf neoantigen vaccine aimed at stopping colorectal and other cancers before they start in people who carry Lynch syndrome. Oct 22, 2026Read more Regulatory News Spotlight FDA510(k) clearance Solventum Clears FDA to Pair Two Wound Therapies Ten months after buying Acera Surgical for $725 million, the 3M spinout won 510(k) clearance to use Acera's synthetic Restrata matrix alongside its own V.A.C. negative-pressure system — the first clearance to formally combine the two technologies. Oct 22, 2026Read more Regulatory News Spotlight FDAFast Track SAB Bio Wins FDA Fast Track for Diabetes Drug The Miami Beach company's fully human antibody therapy, made in genetically engineered cattle rather than human donors, won Fast Track designation for newly diagnosed Stage 3 type 1 diabetes — a disease-modifying bet that targets patients after onset, not before it. Oct 22, 2026Read more Regulatory News Spotlight Health CanadaNew-country approval Cytokinetics Expands MYQORZO Access to Canada Health Canada issued a Notice of Compliance for MYQORZO® (aficamten) on 19 October 2026, authorizing the once-daily cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy — the South San Francisco biopharmaceutical company’s fifth regulatory approval for the drug in under a year. Oct 21, 2026Read more Regulatory News Spotlight FDAExpanded approval Gore Wins FDA Nod for First On-Label Bridging Stent FDA approved an expanded indication for the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis on 14 October 2026, making it the first bridging stent graft approved on-label for both fenestrated and branched endovascular aortic repair in the United States — a use vascular surgeons have relied on off-label for years. Oct 21, 2026Read more Regulatory News Spotlight Series A$103M financing Estuary Launches With $103M for Kidney Gene Therapy The Menlo Park, California company emerged from stealth on 16 October 2026 with $103 million in total committed financing — a $93 million Series A atop an earlier $10 million seed — to push two AAV gene therapies for autosomal dominant polycystic kidney disease toward the clinic. Oct 21, 2026Read more Regulatory News Spotlight FDAFinancing Sensydia Lands $6M to Push Heart Monitor to FDA The Los Angeles medtech company closed an oversubscribed initial funding round on 13 October 2026, led by Colle Capital Partners, to finish the pivotal study its non-invasive Cardiac Performance System needs before FDA will consider it for broader use. Oct 20, 2026Read more Regulatory News Spotlight FDAPublic Offering Verastem Raises $250M, Aligns FDA on Phase 3 The oncology company’s $250 million raise arrives alongside new multi-tumor data for VS-7375 and FDA agreement on the design of a first-line Phase 3 trial in metastatic pancreatic cancer — the disease the oral KRAS G12D inhibitor has targeted hardest so far. Oct 20, 2026Read more Regulatory News Spotlight Series CFinancing Microbiotica Raises £36M to Push MB310 to Phase 2 The Cambridge, England biotech’s first close of a Series C, led by the British Business Bank, funds a Phase 2 trial of MB310, an eight-strain oral gut-bacteria capsule that beat placebo on clinical remission in a Phase 1b ulcerative colitis trial. Oct 19, 2026Read more Regulatory News Spotlight Series C$310M raised OMass Therapeutics Raises $310M Series C The Oxford, UK biotech’s oversubscribed round, the second-largest for a European biotech so far in 2026, funds Phase 2 trials of OMS1620, an oral ACTH-receptor blocker, in congenital adrenal hyperplasia and Cushing's syndrome. Oct 18, 2026Read more Regulatory News Spotlight FDADrug approval Opus Genetics Wins Second FDA Nod for RYZUMVI FDA approved the Research Triangle Park company’s eye drop for presbyopia a day ahead of its goal date, extending a 2023 mydriasis-reversal approval into a second indication Viatris plans to commercialize. Oct 18, 2026Read more Regulatory News Spotlight FDA510(k) clearance SimBioSys Earns FDA Clearance for TumorSight Risk The Chicago AI company’s fourth 510(k) clearance scores a breast-cancer patient’s five- and ten-year recurrence risk from an MRI, pathology and clinical data already on file — no new scan, biopsy or tissue shipment required. Oct 18, 2026Read more Regulatory News Spotlight FDAPMA approval Centinel Spine Completes 2-Level Cervical Disc Set FDA approval for two-level use of prodisc C Nova, announced 14 October 2026, gives the West Chester, Pennsylvania spine-device maker three cervical discs cleared for both one- and two-level replacement, three weeks after it filed for a $100 million IPO. Oct 17, 2026Read more Regulatory News Spotlight EMACHMP opinion Ascendis Wins CHMP Backing for Achondroplasia Drug Yuviwel The EMA’s human-medicines committee recommended EU marketing authorization for once-weekly navepegritide on 16 October 2026, pointing the Copenhagen-area biopharma toward a second regulatory region for the only drug to challenge BioMarin’s eight-year hold on achondroplasia treatment. Oct 17, 2026Read more Regulatory News Spotlight FDAFast Track Marengo Earns Second FDA Fast Track for Tumor Drug The Cambridge, Massachusetts biotech's T-cell-activating antibody, invikafusp alfa, moves from a single-cancer Fast Track designation to any tumor mutational burden-high solid tumor — a tissue-agnostic expansion the company says is a first for its class of immunotherapy. Oct 17, 2026Read more Regulatory News Spotlight IPOFinancing Iambic Prices $150M IPO to Fund AI-Built Cancer Drug Iambic Therapeutics priced its Nasdaq initial public offering at $16.00 a share on 14 October 2026, raising roughly $150 million to push IAM1363 — a HER2 inhibitor designed by the San Diego company’s AI drug-discovery platform — toward a pivotal trial, as its shares rose on their market debut the next day. Oct 16, 2026Read more Regulatory News Spotlight FDA510(k) clearance E2 Clears FDA Hurdle for Blood-Saving Clot Device Endovascular Engineering, known as E2, won FDA 510(k) clearance on 12 October 2026 for Hēlo Return, which it calls the first blood-return system cleared for use with continuous vacuum aspiration — pairing it with the company's existing Hēlo Thrombectomy System to treat pulmonary embolism without the blood loss aspiration thrombectomy typically causes. Oct 16, 2026Read more Regulatory News Spotlight Series BFinancing Soufflé Raises $135M to Push RNA Drug Into the Clinic Soufflé Therapeutics closed an oversubscribed $135 million Series B financing on 13 October 2026, led by Juvia Group, to fund its first clinical trials — in facioscapulohumeral muscular dystrophy (FSHD), heart failure and a third, undisclosed muscle and metabolic program — built on a delivery platform designed to reach cells outside the liver. Oct 16, 2026Read more Regulatory News Spotlight FDA510(k) clearance Vantis Vascular Wins FDA Clearance for 6F CrossFAST The private, San Jose, California company’s larger-lumen 6 French CrossFAST model clears FDA review with room for IVUS and intravascular lithotripsy in complex coronary intervention, and reaches the market in November 2026 alongside the original 5.5F device it has sold since January 2025. Oct 14, 2026Read more Regulatory News Spotlight FDAFast Track designation Leads Biolabs Wins Second FDA Fast Track for BTC Drug The Nanjing, China-based, Hong Kong-listed biotech says the FDA granted the designation nine days after it filed — the second Fast Track nod for its PD-L1/4-1BB bispecific antibody opamtistomig (LBL-024), this time for first-line advanced or metastatic biliary tract cancer, after a January 2026 designation for an unrelated cancer. Oct 14, 2026Read more Regulatory News Spotlight Series AFinancing RougeTx Raises $58 Million Series A for HHT Drug RTX-001 The Naarden, Netherlands company closes a $58 million Series A — co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners with the European Investment Bank’s Aurea co-investment facility — to carry RTX-001, an oral candidate built on two decades of pericyte research at Leiden University Medical Center, toward first-in-human testing in a bleeding disorder with no approved drug. Oct 14, 2026Read more Regulatory News Spotlight FDADrug approval Novartis Earns FDA Nod for First Dermographism Drug Rhapsido (remibrutinib) becomes the first FDA-approved treatment specifically for symptomatic dermographism, expanding its label beyond chronic spontaneous urticaria on Phase 3 RemIND data showing 29.3% of patients reached complete hive response at Week 12, more than double the placebo rate. Oct 13, 2026Read more Regulatory News Spotlight NasdaqIPO Retension Pharmaceuticals Prices $45M Nasdaq IPO The Falls Church, Virginia biopharma priced an upsized offering at $12 a share, raising $45 million to carry its once-daily hypertension pill, RTN-001, through a Phase 2b trial and toward Phase 3. Oct 13, 2026Read more Regulatory News Spotlight CMSMedicare add-on payment icotec Wins Medicare Add-On Payment for CMORE CT The Swiss spine-implant maker's nonmetallic cervicothoracic stabilization system qualifies for up to $60,905 per eligible Medicare case, closing the reimbursement gap that often slows hospital adoption of newly cleared hardware. Oct 13, 2026Read more Regulatory News Spotlight FDABreakthrough Device HeartBeam Wins FDA Breakthrough Status for Heart Attacks FDA granted HeartBeam Breakthrough Device Designation on 5 October 2026 — not for the arrhythmia tool it already sells, but for teaching the same three-vector ECG to flag a possible heart attack before a patient reaches the hospital. Oct 12, 2026Read more Regulatory News Spotlight Series B$150M financing Matchpoint Raises $150M to Push a Covalent Drug to Clinic A $150 million Series B, closed 7 October 2026 and co-led by Nextech Invest and Norwest, is meant to carry Matchpoint's first-in-class oral T-cell modulator from the lab bench into human testing for the first time — a molecule Novartis has already paid to option. Oct 12, 2026Read more Regulatory News Spotlight FDAFirst generic launch Zydus Launches First Generic Adempas Rival in the US Zydus Lifesciences and its manufacturing partner MSN Laboratories began selling the first FDA-approved generic version of riociguat on 5 October 2026, undercutting a Bayer pulmonary-hypertension drug that took in roughly $850 million worldwide last year. Oct 12, 2026Read more Regulatory News Spotlight Series BFinancing Sava Lands $36M Series B Led by Ascensia The London startup's needle-free glucose microsensor drew a strategic equity investment and an exclusive European distribution deal from Ascensia Diabetes Care, as Sava aims for CE approval and launch within 18 to 24 months. Oct 11, 2026Read more Regulatory News Spotlight NasdaqFinancing TRexBio Raises $117M in Nasdaq IPO for Treg Drug The South San Francisco biotech priced its IPO at the bottom of its range on 9 October 2026, with Eli Lilly as its largest shareholder, to fund Phase 2 testing of TRB-061, a Treg-activating therapy for atopic dermatitis and other inflammatory disease. Oct 11, 2026Read more Regulatory News Spotlight FDA510(k) clearance Wellysis Wins FDA Clearance for S-Patch CardioAI The Samsung SDS spin-off’s AI software now reads arrhythmias straight from the ECG patch it already had cleared — a license sold to the remote-monitoring providers and clinical trial operators who run the patch, not to patients directly. Oct 11, 2026Read more Regulatory News Spotlight FDAFast Track designation Vir Biotechnology Wins FDA Fast Track for VIR-5500 The San Francisco biotech's PSMA-targeted, dual-masked T-cell engager cleared a regulatory hurdle on 6 October 2026 for late-line metastatic castration-resistant prostate cancer, as Vir and partner Astellas prepare a pivotal Phase 3 program for 2027. Oct 10, 2026Read more Regulatory News Spotlight FDA510(k) clearance Argus Cognitive Earns FDA Clearance for Neurora The Hanover, New Hampshire software company won FDA 510(k) clearance on 8 October 2026 for an AI tool that scores video and audio from a standard behavioral exam to support autism diagnosis in children from 18 months to 12 years old — a second opinion, the company says, not a standalone verdict. Oct 10, 2026Read more Regulatory News Spotlight FinancingSeries D Medical Microinstruments Lands $125M for Symani The Jacksonville, Florida robotics maker closed a $125 million Series D on 8 October 2026, led by BioStar Capital, to scale commercial reach for its Symani Surgical System — the only FDA-cleared robot built for open microsurgery — and to fund trials including an early feasibility study testing the robot in Alzheimer's disease. Oct 10, 2026Read more Regulatory News Spotlight FDAFast Track Perspective Wins FDA Fast Track for PSV359 in Rare Sarcoma The Seattle radiopharmaceutical company’s third Fast Track Designation targets fibroblast activation protein in solitary fibrous tumors — a cancer with no approved systemic therapy — using the alpha-emitting isotope lead-212. Oct 9, 2026Read more Regulatory News Spotlight Health CanadaDrug approval Lipocine, Verity Win Health Canada Nod for TLANDO A fixed-dose oral testosterone capsule that survived three FDA rejections before its 2022 U.S. approval now has a second market: Health Canada cleared TLANDO on 7 October 2026, and licensee Verity Pharma plans a Canadian launch by year end. Oct 9, 2026Read more Regulatory News Spotlight Series DFinancing Zenflow Lands $52M Series D, Cook Medical Distribution The South San Francisco maker of a reversible, office-placed implant for enlarged prostate closes an oversubscribed Series D led by Cook Medical — which also becomes Spring’s exclusive U.S. distributor, ten months after the device’s FDA premarket approval. Oct 9, 2026Read more Regulatory News Spotlight FDA510(k) clearance MRI2CT Clears FDA Hurdle for AI Spine Imaging The private, Jerusalem-based imaging software company won 510(k) clearance for NextMR Spine, AI software that builds a 3D bone visualization of the lumbar spine and sacrum from a standard diagnostic MRI — no additional CT, no added radiation. Oct 8, 2026Read more Regulatory News Spotlight MHLWDevice authorization Novocure Wins Japan Approval for Pancreatic Cancer Device Japan's Ministry of Health, Labour and Welfare approved Optune Pax on 1 October 2026 for unresectable, locally advanced pancreatic cancer — the Tumor Treating Fields device's third major-market authorization in 2026, after the U.S. and the EU. Oct 8, 2026Read more Regulatory News Spotlight FDABreakthrough Device SeaStar Earns 7th FDA Breakthrough Device Nod The Denver company's Selective Cytopheretic Device now carries seven FDA Breakthrough Device Designations across its indications, the newest aimed at the hyperinflammation that drives roughly a third of sepsis deaths in U.S. hospitals. Oct 7, 2026Read more Regulatory News Spotlight FDA510(k) clearance TELA Bio Wins FDA Clearance for Liora Mesh The Malvern, Pennsylvania company's fully resorbable synthetic scaffold is the first product it has designed and manufactured entirely in its own cleanroom, expanding a soft-tissue reinforcement portfolio built until now on ovine-derived biologics. Oct 7, 2026Read more Regulatory News Spotlight Series BFinancing KymaThera Raises $80M to Advance Cancer Drug K-1728 The San Diego biotech’s Series B, led by Alta Partners, funds a pan-mutant PI3Kα inhibitor the company is developing for both cancer and vascular malformations, with Phase 1 dosing targeted for the fourth quarter of 2026. Oct 7, 2026Read more Regulatory News Spotlight TGACommercial launch Curaleaf Launches First TGA-Registered Cannabis Inhaler Curaleaf International said on 2 October 2026 that its Que Medical Inhalation Device (QMID) is commercially available in Australia and New Zealand, after Australia’s Therapeutic Goods Administration listed it as a Class IIb device — the first inhaled cannabis-extract device of its kind registered in the country, and the second regulatory region, after the EU, to certify it. Oct 6, 2026Read more Regulatory News Spotlight FDAFast Track designation Trethera Lands Second Fast Track for Lung Cancer Drug FDA has granted Trethera Corporation a second Fast Track Designation for TRE-515, its oral deoxycytidine kinase (dCK) inhibitor — this time paired with KRAS G12C inhibitors for non-small cell lung cancer patients who progressed after anti-PD-(L)1 therapy and platinum chemotherapy, announced 1 October 2026, fifteen months after the same drug's first Fast Track nod in prostate cancer. Oct 6, 2026Read more Regulatory News Spotlight FDA510(k) clearance AIRS Medical Clears FDA 510(k) for Body-Fat MRI AI FDA granted AIRS Medical a 510(k) clearance on 5 October 2026 for SwiftSight® Body Composition, AI software that turns a single, under-five-minute MRI scan into quantified measurements of visceral and subcutaneous fat, muscle mass and quality, and liver fat — with SimonMed Imaging named as the first customer to deploy it. Oct 6, 2026Read more Regulatory News Spotlight Series B2Financing UltraSight Raises $24M to Scale AI Cardiac Ultrasound UltraSight has raised a $24 million Series B2, announced 23 September 2026, to expand US hospital deployment of its FDA-cleared software that guides clinicians with no sonography training through diagnostic-quality cardiac ultrasound scans — and to build new workflows for intensive care and mechanical-circulatory-support settings. Oct 4, 2026Read more Regulatory News Spotlight NasdaqPublic offering Pyxis Oncology Prices $110M Raise for MICVO’s Phase 3 Pyxis Oncology priced an underwritten public offering on 30 September 2026 and closed it on 1 October, raising roughly $110 million — and up to $282.6 million if warrants are fully exercised — to carry its lead antibody-drug conjugate, MICVO, toward a planned Phase 3 trial in recurrent or metastatic head and neck cancer. Oct 4, 2026Read more Regulatory News Spotlight FDABreakthrough designation VB Spine Wins FDA Breakthrough Nod for Scoliosis Blood Test FDA granted Breakthrough Device Designation on 29 September 2026 to ScolimiR-3D, a blood test that measures six circulating microRNAs to predict which adolescents with idiopathic scoliosis are likely to progress to a severe curve — the first such designation for a predictive risk-assessment test in the disease, built on research VB Spine began funding in June 2026. Oct 2, 2026Read more Regulatory News Spotlight FDACommercial launch Celcuity Starts Shipping First Wild-Type Breast Cancer Drug Celcuity began U.S. shipments of REVTORPYK (gedatolisib) on 30 September 2026, nearly eleven weeks after FDA approval, once the agency cleared data from a second manufacturing site — making it the first approved therapy for the roughly 60 percent of HR-positive, HER2-negative advanced breast cancers that test negative for a PIK3CA mutation. Oct 2, 2026Read more Regulatory News Spotlight Series BFinancing AnaCardio Raises €62.5M to Fund Heart Drug Phase 2b The private Karolinska Institutet spinout closed an over-subscribed Series B on 30 September 2026, fully funding a 400-patient trial of AC01, an oral contractility drug whose early data showed no tachycardia or arrhythmia signal — the safety problem that has sunk prior heart-failure inotropes. Oct 1, 2026Read more Regulatory News Spotlight CMSMedicare reimbursement EBR Systems Wins Medicare Pay Rise for Its WiSE Heart Device CMS has reclassified the leadless WiSE CRT System into Medicare’s leadless-pacemaker payment category, raising hospitals’ base reimbursement by as much as 93 percent — a reimbursement decision, not a new clearance, that the ASX-listed company says strengthens the commercial case for a device already approved by FDA. Oct 1, 2026Read more Regulatory News Spotlight FDA510(k) clearance QIAGEN Completes US Sepsis Panel Duo With FDA Clearance A 510(k) clearance for a one-hour gram-negative bloodstream-infection panel gives US labs the second half of QIAGEN’s QIAstat-Dx sepsis menu — 33 pathogen targets and 28 resistance markers from a single positive blood culture, seven weeks after the first half cleared. Oct 1, 2026Read more Regulatory News Spotlight FDABreakthrough Device Aidoc Wins Third FDA Breakthrough Nod for X-Ray AI FDA granted Aidoc a Breakthrough Device Designation on 23 September 2026 for CARE Chest X-Ray Triage, an AI tool that flags possible pneumomediastinum and lung collapse on chest X-rays — the third such designation for a product built on Aidoc's CARE foundation model in just over a year. Sep 30, 2026Read more Regulatory News Spotlight FDABreakthrough Therapy Glycomine Lands Breakthrough Status for Rare CDG Drug FDA granted Glycomine Breakthrough Therapy Designation on 23 September 2026 for GLM101, an investigational substrate-replacement therapy for PMM2-CDG — a rare, multisystem disorder of glycosylation with no approved treatment — based on open-label Phase 2a data showing improved ataxia scores over 24 weeks. Sep 30, 2026Read more Regulatory News Spotlight EMACHMP opinion IMPACT Therapeutics Clears CHMP for Ovarian Cancer Drug The EU's Committee for Medicinal Products for Human Use recommended approval on 17 September 2026 of Sepalna (senaparib), a PARP inhibitor IMPACT Therapeutics licensed to Pharmanovia for Europe, as maintenance therapy for advanced ovarian cancer — a first EU regulatory step for a Chinese-discovered oncology drug already approved and reimbursed at home. Sep 30, 2026Read more Regulatory News Spotlight FDAFast Track Quoin Wins First-Ever Fast Track for Peeling Skin Syndrome FDA granted the Ashburn, Virginia micro-cap Fast Track Designation for QRX003 on 22 September 2026 — the first Fast Track ever given for the ultra-rare skin disorder, and the second the same lotion has won this year after Netherton Syndrome in March. Sep 29, 2026Read more Regulatory News Spotlight Series AFinancing Kasvu Raises €30M Series A for TrkB Depression Drug The Helsinki, Finland biotech’s first disclosed institutional round, led by Hadean Ventures with Finland’s state investment company Tesi, advances a TrkB potentiator the company says works without the hallucinogenic effects of psychedelic-based rivals. Sep 29, 2026Read more Regulatory News Spotlight FDA510(k) clearance CapsoVision Clears FDA for AI-Assisted Capsule Endoscopy The Saratoga, California device maker’s AI Highlights reading tool, cleared 25 September 2026, flags suspected small-bowel lesions inside its existing CapsoCam Plus software — built on a predicate device a rival, not CapsoVision, first won FDA authorization for. Sep 29, 2026Read more Regulatory News Spotlight IPOFinancing ADARx Prices $446M IPO to Fund Onvuzosiran The San Diego RNA-interference drugmaker raised $446.3 million in an upsized Nasdaq debut on 24 September 2026, plus an $89 million private placement from its licensing partner AbbVie, to push its lead siRNA candidate through a Phase 3 hereditary angioedema trial. Sep 28, 2026Read more Regulatory News Spotlight FDA510(k) clearance Xenix Medical Clears FDA for Riva Anchor SI Implant FDA cleared the Orlando, Florida implant maker's Riva Anchor Spinopelvic Fixation System on 22 September 2026 — Xenix's third 510(k) clearance of the year — extending its Riva pedicle-fixation platform into the sacroiliac joint with a nano-scale surface treatment the company calls NanoACTIV. Sep 28, 2026Read more Regulatory News Spotlight EMACHMP opinion LEO Pharma Wins CHMP Nod to Treat Teen Eczema CHMP recommended on 17 September 2026 that Anzupgo (delgocitinib) cream be approved across the EU for adolescents aged 12 to 17 with moderate-to-severe chronic hand eczema — based on a dedicated Phase 3 trial in 98 teenagers — with a European Commission decision still to come. Sep 28, 2026Read more Regulatory News Spotlight FDA510(k) clearance Marani Health Clears FDA for M•care Fetal Monitor The Mayo Clinic-linked, Twin Cities-area startup won FDA 510(k) clearance for a wearable that moves a prescribed test of fetal and maternal heart activity out of the clinic and onto a pregnant patient's body at home — becoming the third maker of a cleared home fetal-monitoring wearable, not the first. Sep 27, 2026Read more Regulatory News Spotlight EMACHMP opinion Incyte Lands EU Backing for First Oral HS Pill CHMP's 17 September 2026 positive opinion recommends EU approval of Povofortay (povorcitinib) for hidradenitis suppurativa patients who fail or can't tolerate anti-TNF biologics — povorcitinib's first regulatory green light anywhere, though a US decision and an EU launch both still lie ahead. Sep 27, 2026Read more Regulatory News Spotlight Health CanadaDrug approval Rhythm Expands IMCIVREE to Acquired Obesity in Canada Health Canada's 22 September 2026 approval extends IMCIVREE to weight management in acquired hypothalamic obesity, a condition caused by injury to the brain's hunger-regulating hypothalamus — the drug's fourth on-label use, following the same indication's US approval five months earlier. Sep 27, 2026Read more Regulatory News Spotlight FDADrug approval Mirum Wins FDA Nod for Third FOP Drug Atebrioz The oral ALK2 inhibitor becomes the third FDA-approved treatment for fibrodysplasia ossificans progressiva in three years, arriving five weeks after Regeneron's Pasatru and landing a day ahead of its own Priority Review deadline. Sep 26, 2026Read more Regulatory News Spotlight FDAOTC clearance Biolinq’s Shine Clears FDA for OTC Sale A year after its FDA debut as a prescription-only device, the San Diego company's intradermal glucose sensor becomes the third biosensor cleared to sell over the counter, alongside Dexcom's Stelo and Abbott's Lingo. Sep 26, 2026Read more Regulatory News Spotlight Series DFinancing Precision Neuroscience Raises $250M for BCI The New York brain-computer interface maker's oversubscribed Series D, co-led by Bill Ackman's Pershing Square Inc. and the newly formed Ackman Oxman Institute, funds its Layer 7 Cortical Interface through further FDA review beyond its existing 30-day clearance. Sep 26, 2026Read more Regulatory News Spotlight EMACHMP opinion Betta’s Gevalka Clears CHMP for Lung Cancer The Committee for Medicinal Products for Human Use adopted a positive opinion on 17 September 2026 recommending EU marketing authorization for Gevalka (ensartinib), an ALK inhibitor Hangzhou-listed Betta Pharmaceuticals develops outside China through its wholly owned U.S. subsidiary, Xcovery Holdings. Sep 25, 2026Read more Regulatory News Spotlight Series CFinancing BigHat Biosciences Lands $75M for AI Antibodies The San Mateo, California company closed an oversubscribed-adjacent Series C on 24 September 2026, co-led by DFJ Growth and Premji Invest, weeks after dosing the first patient in a Phase 1/2 trial of BHB810, an antibody-drug conjugate its AI-and-wet-lab platform designed for gastric cancer. Sep 25, 2026Read more Regulatory News Spotlight EMACHMP opinion CHMP Recommends Zealand’s Zeydovio for Bowel Disease Europe's medicines committee backed glepaglutide, a twice-weekly GLP-2 analog, for adults with short bowel syndrome — less than two years after the same drug drew a rejection letter from FDA. Sep 24, 2026Read more Regulatory News Spotlight Financing$90M round HighLife Raises $90M for US Valve Trial, EU Growth The Paris company's largest round to date will fund a U.S. pivotal study of its transseptal mitral valve replacement and speed commercial expansion across Europe, four years after FDA cleared the trial to begin. Sep 24, 2026Read more Regulatory News Spotlight FDA510(k) clearance TriSalus Wins FDA Clearance for TriNav Advance The Westminster, Colorado company's fifth Pressure-Enabled Drug Delivery catheter reaches small and distal vessels for the first time, without giving up the reflux protection that defines the platform, and begins a limited market release within weeks. Sep 24, 2026Read more Regulatory News Spotlight FDA510(k) clearance Traferox Lands FDA Clearance for X°Port Heart System The Toronto transplant-program spin-out won 510(k) clearance on 22 September 2026 for X°Port, a static preservation system that holds a donor heart at 10°C rather than the roughly 4°C of conventional ice storage — its second FDA clearance in three months, after a lung-perfusion system approved in July. Sep 23, 2026Read more Regulatory News Spotlight FDADe Novo authorization Powerful Medical Wins First FDA Nod for AI-ECG Tool The Bratislava-founded company’s Queen of Hearts model becomes the first AI-ECG software FDA has authorized specifically to flag acute heart attacks for urgent cardiologist review, a De Novo grant that arrives 18 months after a Breakthrough Device Designation and follows a European rollout the company says caught more than 120,000 heart attacks last year. Sep 23, 2026Read more Regulatory News Spotlight FinancingIPO Electra Therapeutics Prices $350M IPO for sHLH Drug The South San Francisco biotech upsized its Nasdaq debut to $350 million on 17 September 2026, earmarking roughly $220 million to carry ipsoprubart — an antibody already holding FDA Fast Track, FDA Breakthrough Therapy and EMA PRIME status — through a pivotal trial already dosing patients. Sep 22, 2026Read more Regulatory News Spotlight FDADrug approval Curium Wins FDA Approval for First Radioligand Rival The Paris-based radiopharmaceutical maker won FDA approval for BEXLUTRY on 14 September 2026, the first radioligand therapy cleared through the 505(b)(2) pathway as an equivalent to Novartis’s Lutathera — three months after a Delaware court invalidated the patents that stood in its way. Sep 22, 2026Read more Regulatory News Spotlight FinancingSeries A Dialybrid Raises €15M, Implants First Vascular Graft The Milan biomaterials company closed a €15 million Series A on 22 September 2026 and used the same announcement to disclose the first human implant of Silkothane, a silk-and-polyurethane arteriovenous graft designed to gradually integrate into hemodialysis patients rather than sit as inert plastic. Sep 22, 2026Read more Regulatory News Spotlight TGADevice authorization Koning Health Wins TGA Approval for Breast CT System The Norcross, Georgia company’s compression-free, cone-beam 3D scanner becomes authorized for commercial supply in Australia, extending a technology FDA first approved nearly a decade ago into a fifth market, with Brisbane Radiology named as the first buyer. Sep 21, 2026Read more Regulatory News Spotlight MHLWDrug approval SK Biopharmaceuticals Completes Japan Epilepsy Approval Japan's Ministry of Health, Labour and Welfare approved cenobamate for partial-onset seizures on 16 September 2026, closing out a regulatory sweep across Korea, China and Japan for the Seongnam-based drugmaker and its partner Ono Pharmaceutical. Sep 21, 2026Read more Regulatory News Spotlight Series EFinancing Circle Pharma Raises $92.5M Series E for Cancer Drug The South San Francisco biotech's oversubscribed round, led by The Column Group with Eli Lilly participating, funds CID-165, a first-in-class macrocycle designed to block a protein interaction that current CDK4/6 inhibitors don't touch, toward a first-quarter 2027 clinical start. Sep 21, 2026Read more Regulatory News Spotlight FinancingSeries C Sling Nets $123M to Push Eye Drug Into Phase 3 The Ann Arbor biotech closed a $123 million Series C on 16 September 2026, led by Forbion, to carry linsitinib — an oral pill it says is the only IGF-1R inhibitor in late-stage development for thyroid eye disease — through its pivotal ORBIT trial and toward a filing that would challenge Amgen's infused Tepezza. Sep 20, 2026Read more Regulatory News Spotlight FDARMAT designation Cyllene Wins FDA RMAT Status for Bladder Gene Therapy The Paris company's EG110A, a one-time injection that silences the sensory nerves behind neurogenic detrusor overactivity after spinal cord injury, now holds Regenerative Medicine Advanced Therapy designation on the strength of an 88% drop in incontinence episodes — its third FDA designation in under a year. Sep 20, 2026Read more Regulatory News Spotlight FinancingSeries A RegCell Raises $66M for Nobel-Backed Treg Therapy The Emeryville, California company’s $44 million Series A and a second non-dilutive grant from Japan’s AMED will fund an FDA IND submission and a second autoimmune program for the cell therapy platform built on Shimon Sakaguchi’s Nobel-winning regulatory T-cell science. Sep 19, 2026Read more Regulatory News Spotlight FDA510(k) clearance Shoulder Innovations Clears FDA Hurdle for N-22 Implant The Grand Rapids, Michigan company’s titanium N-22 Humeral Head, cleared 10 September 2026 and launched immediately, gives surgeons a metal-hypersensitive option in anatomic shoulder replacement to match the reverse-arthroplasty implant it cleared in January. Sep 19, 2026Read more Regulatory News Spotlight EU MDRCE Mark FemPulse Earns CE Mark for Wearable Bladder Ring The Minnesota company’s self-inserted, silicone neuromodulation ring won EU MDR certification on 17 September 2026, offering the estimated one in five women worldwide with overactive bladder a non-surgical alternative to medication or an implant. Sep 19, 2026Read more Regulatory News Spotlight FinancingSeries A Matisse Raises €14M for Phase 2 Sepsis Drug Trial The Dutch biotech closed the round six months after FDA cleared isupartob sodium’s IND and granted it Fast Track designation, funding a trial of a first-in-class drug that neutralizes the histones sepsis releases into the bloodstream. Sep 18, 2026Read more Regulatory News Spotlight FDABreakthrough Device CorTec Lands Second FDA Breakthrough Nod for BCI The same fully implanted Brain Interchange hardware that is already in an FDA feasibility study for stroke rehabilitation has now earned a second Breakthrough Device Designation, this one for letting people with paralysis in all four limbs control a computer by thought. Sep 18, 2026Read more Regulatory News Spotlight FDADrug approval Scholar Rock Wins FDA Nod for First SMA Muscle Drug ISEMBYLD (apitegromab-mstn) is designed to be added on top of an existing SMN2-targeted therapy rather than replace it, and in the pivotal SAPPHIRE trial it moved a 12-month motor-function score that placebo patients did not. Sep 18, 2026Read more Regulatory News Spotlight FDADrug approval Pharming Wins FDA Nod to Extend Joenja to Kids The Leiden, Netherlands company’s leniolisib now covers children ages 4 to 11 weighing at least 27 kilograms with Activated PI3K-Delta Syndrome, an ultra-rare primary immunodeficiency — the first FDA-approved APDS treatment for that age group, cleared six weeks ahead of its target review date. Sep 17, 2026Read more Regulatory News Spotlight CE markDevice authorization UpFront Diagnostics Earns CE Mark for Stroke Test The Cambridge, UK startup’s LVOne reads two blood biomarkers from a fingerstick sample to flag large-vessel-occlusion stroke before a patient reaches hospital, and is already piloting with London Ambulance Service crews across north London. Sep 17, 2026Read more Regulatory News Spotlight FDA510(k) clearance Emboline Clears FDA Hurdle for TAVR Debris Filter The Santa Cruz, California company’s Emboliner protects the brain and the rest of the body during transcatheter aortic valve replacement, and beat the only other cleared device on technical success and debris capture in a 522-patient head-to-head trial. Sep 17, 2026Read more Regulatory News Spotlight FDA510(k) clearance Beta Bionics Wins FDA Clearance for Mint Patch Pump The Irvine, California company becomes the second manufacturer with a cleared tubeless insulin patch pump in the United States, filed a 510(k) for its next-generation 3D Intelligence dosing algorithm the same day, and set a full U.S. launch for the first quarter of 2027. Sep 15, 2026Read more Regulatory News Spotlight FDABreakthrough designation Armata Wins Breakthrough Status for Phage Therapy AP-SA02 The Los Angeles bacteriophage developer now holds QIDP, Fast Track and Breakthrough Therapy designations for AP-SA02, an intravenous phage cocktail given alongside antibiotics for complicated Staphylococcus aureus bacteremia, on Phase 2 data showing 100% relapse-free response versus 75% on placebo. Sep 15, 2026Read more Regulatory News Spotlight FDABreakthrough designation Juniper Lands Breakthrough Status for Hypoxia PET Tracer The New Jersey company’s F-MISO imaging agent, licensed from Memorial Sloan Kettering, maps tumor hypoxia so that patients with HPV-positive oropharyngeal cancer whose tumors are not oxygen-starved can be treated with 30 Gray instead of 70. The designation is the first for a hypoxia tracer in the United States. Sep 15, 2026Read more